Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4242 - Influence of an intronic polymorphism in the MITF gene, of melanogenic pathway, in the risk and the prognosis of cutaneous melanoma


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Melanoma


Caroline Torricelli


Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377


C. Torricelli1, C. Oliveira1, B. Sá Carvalho2, J.K. Silva1, G.V.B. Gomez1, W.D.L. Oliveira1, J.A. Rinck-Junior3, A.M. Moraes3, M.M. Ortega4, C.S.P. Lima3, G.J. Lourenço1

Author affiliations

  • 1 Laboratory Of Cancer Genetics, Faculty Of Medical Sciences, University of Campinas, 13083-888 - Campinas/BR
  • 2 Department Of Statistics - Institute Of Mathematics, Statistics And Computer Science, University of Campinas, 13083-859 - Campinas/BR
  • 3 Department Of Internal Medicine, University of Campinas, 13083-888 - Campinas/BR
  • 4 Laboratory Of Cell And Molecular Tumor Biology And Bioactive Compounds, São Francisco University, 12916900 - Bragança Paulista/BR


Abstract 4242


We identified more than 12,000 new single nucleotide polymorphisms (SNPs) associated with cutaneous melanoma (CM) risk in 103 patients and 103 controls, using large-scale genotyping with DNA microarrays. A bioinformatics analysis showed that MITF c.938-325G>A SNP, involved in melanogenesis and located in regulatory sequence of mRNA processing (splicing), may alter the binding sites of splicing proteins, such as SF1 and hnRNP A1. However, the role of this SNP in the risk and prognosis of CM patients is still unknown. We aim to evaluate the influence of this SNP on the risk and prognosis of CM, clinical and tumor characteristics, and MITF, SF1 and HNRNPA1 levels.


MITF genotypes of 262 CM patients and 280 controls were identified in DNA by RT-PCR. Patients were treated with conventional protocols. Gene expressions were evaluated by qPCR using RNA of 73 controls. The differences between groups were assessed by chi-square, logistic regression, t test and ANOVA. Progression-free (PFS) and overall survival (OS) times were estimated by Kaplan-Meier and Cox methods.


The frequency of the AA variant genotype was higher in patients than in controls (26.8% vs. 21.1%, P = 0.03). Individuals with referred genotype were under 1.60-fold increased risk of CM (95% CI: 1.02-2.52) than others. The frequency of GA or AA genotypes was more common in patients with lower phototype (I-III) (90.8% vs. 80.9%, P = 0.04) and with vertical tumors (83.7% vs. 67.5%, P = 0.04). The median of follow-up was 76 months. At 60 months, PFS (53.4% vs. 71.6%, P = 0.005, Cox: HR: 1.84, P = 0.006) and OS (76.2% vs. 82.4%, P = 0.02, Cox: HR: 1.79, P = 0.03) were shorter in patients with AA genotype than others. We observed similar frequencies of MITF (1.2 vs. 1.1 vs. 1.0 arbitrary units (AUs), P = 0.30), SF1 (1.1 vs. 1.2 vs. 1.0 AUs, P = 0.94) and HNRNPA1 (1.1 vs. 1.3 vs. 1.3 AUs, P = 0.61) mRNA levels in individuals with distinct genotypes.


Our results suggest, for the first time, that MITF c.938-325G> SNP is an important inherited factor for the risk and prognosis of CM. Our findings, once validated in additional studies, will contribute to personalize the therapy of CM patients.

Clinical trial identification

Legal entity responsible for the study

University of Campinas (UNICAMP)


São Paulo Research Foundation (FAPESP)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.